The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
CCL
Vol.
37
No.
11
November 28, 2014
- PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III
- Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer
- Phase III Tumor Treating Fields Trial Halted Following Positive Results in Interim Analysis
- Study: Keytruda Improves PFS In Ipilimumab-Refactory Disease
- Addition of Immune Stimulant To Yervoy Therapy Increases Overall Survival, Study Says
- Phase II Trial of BIND-014 Shows Anti-Tumor Activity in Q3W Arm
- Opdivo Study Shows 41 Percent One-Year Survival In Patients With at Least Two Past Therapies
- Galeterone Shows Potential In CRPC AR Variants, Study Says
- NCI CTEP-Approved Trials For the Month of November
- Cyramza Combination Approved In Advanced Gastric Cancer
TCL
Vol.
40
No.
45
December 05, 2014
- Top NCI Officials Pledge No Further Consolidation of Clinical Trials System
- Urgent FDA Action Turns Power Morcellation Into Rarely Used Gynecological Procedure
- Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light
- Varmus’s 2016 Bypass Budget Seeks “Modest” Increase of $823 Million
- NYC Doctor Pays $2.35 Million To Settle False Claims Act Suit Over Radiosurgery Reimbursements
- Drugs and Targets: Blincyto granted accelerated approval in R/R ALL
- In Brief: David Chambers named deputy director for implementation science at NCI DCCPS
TCL
Vol.
40
No.
46
December 12, 2014
- Is Everyone in Academic Medicine Unhappy? Or is it Just MD Anderson?
- Senate Debates $1.1 Trillion “Cromnibus” Bill That Includes a $150 Million Increase for NIH
- Daniel Hayes Elected President of ASCO
- Varmus Discusses Grant Policy, Changes in Congress and Ebola
- NCI’s Douglas Lowy and John Schiller Honored with National Medal
- Obituary: Lee Wattenberg, 92, “Father of Chemoprevention”
- Regulatory Approvals: Gardasil 9 approved, which covers five additional HPV types
- In Brief: Weldon Gage named CFO at MD Anderson Cancer Center
TCL
Vol.
40
No.
47
December 19, 2014
- Congress Plans to Accelerate Development of Drugs, Devices
- Research Advocates Prepare to Face Republican-led Congress
- Half-Percent NIH, NCI Budget Raise Is Not Enough, Advocates Say
- Conversation with The Cancer Letter: Is Republican Control Better Than Two-Party Stalemate?
- ACS President & COO Resigns Unexpectedly; Was Seen as Contender for CEO Position
- ODAC To Advise FDA on First Biosimilars Application Jan. 7
- NCI Advisory Board Approves Three Concepts
- Editorial: A Record-Breaking Year for The Cancer Letter
- Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC
- In Brief: Fabien Calvo named chief scientific officer of Cancer Core Europe
CCL
Vol.
37
No.
12
December 26, 2014
- FDA Grants Approvals to Lynparza, Blincyto, Xgeva, Gardasil 9 and Cyramza
- Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study
- Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk
- Imbruvica Improves PFS, OS In Phase III CLL Study
- Blincyto Demonstrates Response In Minimal Residual Disease ALL
- Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up
- Amgen Cancels Rilotumumab Trials in Gastric Cancer
- NCI CTEP-Approved Trials For the Month of December